Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements
- PMID: 38137002
- PMCID: PMC10742895
- DOI: 10.3390/genes14122180
Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements
Abstract
Standard cytogenetic techniques (chromosomal banding analysis-CBA, and fluorescence in situ hybridization-FISH) show limits in characterizing complex chromosomal rearrangements and structural variants arising from two or more chromosomal breaks. In this study, we applied optical genome mapping (OGM) to fully characterize two cases of complex chromosomal rearrangements at high resolution. In case 1, an acute myeloid leukemia (AML) patient showing chromothripsis, OGM analysis was fully concordant with classic cytogenetic techniques and helped to better refine chromosomal breakpoints. The OGM results of case 2, a patient with non-Hodgkin lymphoma, were only partially in agreement with previous cytogenetic analyses and helped to better define clonal heterogeneity, overcoming the bias related to clonal selection due to cell culture of cytogenetic techniques. In both cases, OGM analysis led to the identification of molecular markers, helping to define the pathogenesis, classification, and prognosis of the analyzed patients. Despite extensive efforts to study hematologic diseases, standard cytogenetic methods display unsurmountable limits, while OGM is a tool that has the power to overcome these limitations and provide a cytogenetic analysis at higher resolution. As OGM also shows limits in defining regions of a repetitive nature, combining OGM with CBA to obtain a complete cytogenetic characterization would be desirable.
Keywords: chromothripsis; complex karyotype; cytogenetics; hematologic neoplasms; optical genome mapping.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Optical genome mapping enables constitutional chromosomal aberration detection.Am J Hum Genet. 2021 Aug 5;108(8):1409-1422. doi: 10.1016/j.ajhg.2021.05.012. Epub 2021 Jul 7. Am J Hum Genet. 2021. PMID: 34237280 Free PMC article.
-
Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping.Am J Hum Genet. 2021 Aug 5;108(8):1423-1435. doi: 10.1016/j.ajhg.2021.06.001. Epub 2021 Jul 7. Am J Hum Genet. 2021. PMID: 34237281 Free PMC article.
-
Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML/MDS patients.Int J Cancer. 2022 Jun 15;150(12):1998-2011. doi: 10.1002/ijc.33942. Epub 2022 Feb 7. Int J Cancer. 2022. PMID: 35064925
-
Genomic structural variants analysis in leukemia by a novel cytogenetic technique: Optical genome mapping.Cancer Sci. 2024 Nov;115(11):3543-3551. doi: 10.1111/cas.16325. Epub 2024 Aug 24. Cancer Sci. 2024. PMID: 39180374 Free PMC article. Review.
-
Cytogenetics and the Revolution of Optical Genome Mapping in the Diagnosis of Diseases.Discov Med. 2024 Sep;36(188):1780-1788. doi: 10.24976/Discov.Med.202436188.164. Discov Med. 2024. PMID: 39327241 Review.
Cited by
-
Optical Genome Mapping: A Machine-Based Platform in Cytogenomics.Methods Mol Biol. 2024;2825:113-124. doi: 10.1007/978-1-0716-3946-7_5. Methods Mol Biol. 2024. PMID: 38913305
-
Chromothripsis in myeloid malignancies.Ann Hematol. 2024 Oct;103(10):3955-3962. doi: 10.1007/s00277-024-05814-9. Epub 2024 May 30. Ann Hematol. 2024. PMID: 38814446 Free PMC article. Review.
References
-
- Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., Kundgen A., Lübbert M., Kunzmann R., Giagounidis A.A.N., et al. New Insights into the Prognostic Impact of the Karyotype in MDS and Correlation with Subtypes: Evidence from a Core Dataset of 2124 Patients. Blood. 2007;110:4385–4395. doi: 10.1182/blood-2007-03-082404. - DOI - PubMed
-
- Schanz J., Tüchler H., Solé F., Mallo M., Luño E., Cervera J., Granada I., Hildebrandt B., Slovak M.L., Ohyashiki K., et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia after MDS Derived from an International Database Merge. J. Clin. Oncol. 2012;30:820–829. doi: 10.1200/JCO.2011.35.6394. - DOI - PMC - PubMed
-
- He R., Wiktor A.E., Hanson C.A., Ketterling R.P., Kurtin P.J., Van Dyke D.L., Litzow M.R., Howard M.H., Reichard K.K. Conventional Karyotyping and Fluorescence In Situ Hybridization: An Effective Utilization Strategy in Diagnostic Adult Acute Myeloid Leukemia. Am. J. Clin. Pathol. 2015;143:873–878. doi: 10.1309/AJCPP6LVMQG4LNCK. - DOI - PubMed
-
- Coleman J.F., Theil K.S., Tubbs R.R., Cook J.R. Diagnostic Yield of Bone Marrow and Peripheral Blood FISH Panel Testing in Clinically Suspected Myelodysplastic Syndromes and/or Acute Myeloid Leukemia: A Prospective Analysis of 433 Cases. Am. J. Clin. Pathol. 2011;135:915–920. doi: 10.1309/AJCPW10YBRMWSWYE. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials